Next week, the kidney research community will gather in Boston for the 8th CKD Summit 2026, a premier event that brings together clinicians, researchers, and industry experts to discuss the latest advances in chronic kidney disease (CKD) research and therapy development. The summit serves as a platform to share scientific discoveries, explore emerging technologies, and foster collaborations that can accelerate progress in nephrology.

This year’s summit features a dedicated ADPKD-focused day, highlighting the latest insights into polycystic kidney disease, including disease modeling, biomarker identification, therapeutic strategies, and translational research approaches. Key topics on this day include the heterogeneity of disease onset and progression, challenges in preclinical model development, and new strategies to optimize long-term studies of novel ADPKD therapeutics.

InnoSer is proud to be an event sponsor and will present a research poster showcasing new validation data from our adult-onset Pkd1 cKO mice. ADPKD is a complex disease characterized by variable onset and progression, making preclinical models that capture this heterogeneity essential for drug discovery.

Expanding our ADPKD mouse model platform with an adult-onset P40 mouse model

This year at the 8th CKD Summit 2026, InnoSer will present a research poster featuring new validation data of an adult-onset ADPKD mouse model. It is well-established that ADPKD shows heterogeneous disease onset and progression in patients, necessitating preclinical models that capture the heterogeneous disease penetration observed in patients. Therefore, new datasets in our adult-onset P40 mouse model further expand our existing platform (namely, our P10 and P18 mouse models) with a mouse model that offers extended therapeutic dosing windows, making it suitable for disease prevention and biomarker identification studies, as well as for long-term assessment of treatment efficacy and potential adverse effects of novel ADPKD therapeutics. 

Key research highlights presented at the 8th CKD Summit 2026 of the P40 mouse model of ADPKD include:

• Establishment of an adult-onset P40 model by conditional knock-out of Pkd1 at PND40
• Progressive kidney dysfunction captured longitudinally from PND49 to PND180
• Kidney volume (KV/BW), kidney weight/body weight (KW/BW), and blood urea nitrogen (BUN) changes modeling ADPKD progression
• Progressive cyst formation and kidney enlargement in P40 mice

Complementing our P10 and P18 mouse models, representing the industry gold standard ADPKD mouse models, frequently used across multiple compound lead screening and preclinical efficacy studies due to their rapid disease phenotype, the P40 mouse model offers you the possibility to perform long-term studies in a comparable ADPKD phenotype setting.

Want to see how the P40 model compares to our other ADPKD models? Check out our blog post on the P10, P18 and P40 mouse models for the full details.